Terbium sensitized luminescence for the determination of ketoprofen in pharmaceutical formulations.
This paper explores an ultra-sensitive luminescence method for the determination of Ketoprofen (KP) in pharmaceutical formulations. The technique is indirect and exploits the luminescence enhancement of terbium (Tb(3+)) by complexation with KP (Tb(3+)-KP), which was monitored at respective excitation and emission wavelengths of lambda(ex) = 258 nm and lambda(em) = 549 nm. The effect of varying the Tb(3+) concentration and using multiple solvents was examined to determine optimal experimental conditions. Maximum sensitization was accomplished in the presence of methanol where the most favourable condition for the formation of the complex was recorded at a level of 1.0 x 10(-5) M of Tb(3+). Under these optimum experimental conditions, linear calibration curve was obtained in the range of 2.8 x 10(-7)-3.1 x 10(-6) M with a detection limit of 8.7 x 10(-8) M. The technique was validated with 'working' reference standards and produced relative standard deviations < 2% indicating that the reproducibility was highly acceptable. The proposed method was successfully applied to assays of KP in pharmaceutical formulations with average recoveries of 92-98%. The results were found to be in good agreement with those obtained by HPLC. The method is highly suited for general applications of this nature.
Al-Kindy
Salma M Z
SM
Department of Chemistry, Sultan Qaboos University, College of Science, Box 36, Al-Khod 123, Muscat, Sultanate of Oman. alkindy@squ.edu.om
Al-Harasi
Zakiya
Z
Suliman
Fakhr Eldin O
FE
Al-Hamadi
Abdalla
A
Pillay
Avin
A
D002138:Calibration; D007660:Ketoprofen / Q000032:analysis*; D008163:Luminescent Measurements / Q000379:methods*; D000432:Methanol; D004364:Pharmaceutical Preparations / Q000032:analysis; D012015:Reference Standards; D013725:Terbium / Q000737:chemistry*
D004364:Pharmaceutical Preparations; D013725:Terbium; D007660:Ketoprofen; D000432:Methanol
Talanta. 2004 Dec 15;64(5):1343-50
18969752
J Chromatogr A. 2005 May 6;1073(1-2):341-6
15909539
J Chromatogr A. 2005 Aug 19;1084(1-2):152-9
16114248
J Chromatogr A. 1998 Mar 13;799(1-2):301-7
9550108
Spectrochim Acta A Mol Biomol Spectrosc. 2003 Nov;59(13):3085-92
14583283
J Pharm Biomed Anal. 2007 Mar 12;43(4):1221-7
17127029
Talanta. 2003 Oct 17;61(2):221-31
18969181
J Pharm Biomed Anal. 2004 Oct 29;36(2):393-9
15496335
Biomed Chromatogr. 1997 May-Jun;11(3):137-42
9192105
Analyst. 1999 Jul;124(7):1079-84
10736863
J Pharm Biomed Anal. 2004 Nov 15;36(3):625-9
15522540
Farmaco. 2003 Jun;58(6):419-22
12767380
J Pharm Biomed Anal. 2007 Jul 27;44(3):824-8
17459642
Anal Chem. 1997 May 1;69(9):1793-9
21639306
Mol Pharmacol. 2001 Apr;59(4):901-8
11259636
Spectrochim Acta A Mol Biomol Spectrosc. 2007 Mar;66(3):676-80
16859964
J Chromatogr A. 2001 Apr 20;914(1-2):299-314
11358225
Spectrochim Acta A Mol Biomol Spectrosc. 2008 Dec 15;71(4):1461-5
18586554
J Pharm Biomed Anal. 2004 Jun 29;35(4):807-16
15193725
J Chromatogr A. 2002 Dec 27;982(2):293-301
12489886
Cancer Lett. 1999 Dec 1;147(1-2):187-93
10660105
J Pharm Biomed Anal. 2001 Feb;24(4):587-94
11272315
J Chromatogr A. 2001 Apr 20;914(1-2):211-22
11358215
J Chromatogr A. 2005 Feb 18;1065(2):279-85
15782974
Talanta. 1998 Mar;45(5):829-34
18967067
Luminescence. 2007 Jul-Aug;22(4):294-301
17373027